Handelsbanken Fonder AB Takes $806,000 Position in LeMaitre Vascular, Inc. $LMAT

Posted by Stanley Muller on Aug 20th, 2026

Handelsbanken Fonder AB bought a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 8,400 shares of the medical instruments supplier’s stock, valued at approximately $806,000.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its position in LeMaitre Vascular by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after purchasing an additional 21,946 shares during the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of LeMaitre Vascular by 3.6% during the first quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock worth $161,224,000 after purchasing an additional 51,825 shares during the last quarter. First Trust Advisors LP increased its stake in shares of LeMaitre Vascular by 6.2% in the first quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier’s stock valued at $108,959,000 after buying an additional 57,931 shares in the last quarter. State Street Corp increased its stake in shares of LeMaitre Vascular by 0.8% in the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock valued at $65,447,000 after buying an additional 6,130 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of LeMaitre Vascular by 20.1% in the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after buying an additional 105,921 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $83.87 on Thursday. LeMaitre Vascular, Inc. has a 52-week low of $78.65 and a 52-week high of $118.01. The stock has a market cap of $1.92 billion, a PE ratio of 29.43, a PEG ratio of 2.35 and a beta of 0.53. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. The firm’s 50 day moving average price is $94.78 and its two-hundred day moving average price is $99.72.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). The business had revenue of $70.38 million for the quarter, compared to the consensus estimate of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 EPS. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio is currently 35.09%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, August 14th. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Wells Fargo & Company lowered their price target on shares of LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $110.60.

Check Out Our Latest Research Report on LeMaitre Vascular

LeMaitre Vascular Profile

(Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.